statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2023 Healthy Future Report, sharing its actions to promote healthy people, a healthy planet and a healthy business. The...

Tevas 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva...

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab)

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Investment analysts at Zacks Research increased their Q3 2025 earnings estimates for shares of Teva Pharmaceutical Industries in a...

Q3 2025 EPS Estimates for Teva Pharmaceutical Industries Limited Raised by Zacks Research (NYSE:TEVA)

Lauren Clason | (TNS) CQ-Roll Call
A recent tweak to a Medicaid formula could be behind the shake-up to inhaler products, a series of changes that have both benefited and harmed patients with asthma...

Experts say Medicaid rebate change is behind inhaler price cuts

Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA  Free Report) from an underweight rating to a neutral rating in a research report released on Friday...

Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded by JPMorgan Chase & Co. to Neutral

EVP, CFO Eliyahu Kalif Sells 77,550 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

AXQ Capital LP increased its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA  Free Report) by 23.2% in the 3rd quarter, according to its most recent disclosure with the...

AXQ Capital LP Has $287,000 Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

This is a signal that TEVA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Teva Pharmaceutical Industries (TEVA, $13.44) RSI Indicator left the overbought zone on March 04, 2024

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Volume	6.1M
52-Wk High	$14.47
52-Wk Low	$7.09

Current Price	$14.10
Prev Close	$13.98
Open	$13.91
Dividend Yield	0.00%
50-Day Moving Average	$13.55
Beta	0.96
Avg. Volume	8.91M
PE Ratio	-29.63

52-Week High	$14.47
52-Week Low	$7.09
Market Capitalization	$15.67B
EPS	-$0.4718
Price to Book	2.09
Revenue Per Employee	$425,616.51
Enterprise Value/EBITDA	6.79

TEVA Teva- Pharmaceutical Industries Ltd. - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals